Literature DB >> 9045943

Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome.

S Sakurada1, T Kato, K Mashiba, S Mori, T Okamoto.   

Abstract

To examine the role of vascular endothelial growth factor (VEGF) in the development of edema associated with Kaposi's sarcoma (KS) in acquired immunodeficiency syndrome (AIDS), we exploited animal model systems to detect the activity that induces vascular hyper-permeability (VHP) using cultured AIDS-KS spindle cells. Cultured AIDS-KS spindle cells and conditioned medium (AIDS-KS-CM) that had been semi-purified through a heparin affinity column were tested for the ability to induce VHP in animals. The AIDS-KS spindle cells and AIDS-KS-CM induced VHP that was histamine-independent. The VHP-inducing activity was detected in the 0.5 M NaCl fraction from the heparin affinity column and was blocked by anti-VEGF neutralizing antibody. In addition, the production of VEGF was demonstrated in fresh AIDS-KS tissue as well as in cultured AIDS-KS cells, while control cells were negative for VEGF production. From these observations, we concluded that AIDS-KS cells produce a factor(s) that promotes VHP, and this factor could be VEGF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9045943      PMCID: PMC5921004          DOI: 10.1111/j.1349-7006.1996.tb03124.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  42 in total

1.  Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs.

Authors:  A A MILES; E M MILES
Journal:  J Physiol       Date:  1952-10       Impact factor: 5.182

Review 2.  Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  B Ensoli; G Barillari; R C Gallo
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

3.  Simple method for quantitation of enhanced vascular permeability.

Authors:  K Udaka; Y Takeuchi; H Z Movat
Journal:  Proc Soc Exp Biol Med       Date:  1970-04

4.  Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products.

Authors:  H F Dvorak; N S Orenstein; A C Carvalho; W H Churchill; A M Dvorak; S J Galli; J Feder; A M Bitzer; J Rypysc; P Giovinco
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

5.  Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells.

Authors:  S Nakamura; S Z Salahuddin; P Biberfeld; B Ensoli; P D Markham; F Wong-Staal; R C Gallo
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

6.  Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells.

Authors:  F L Sciacca; M Stürzl; F Bussolino; M Sironi; H Brandstetter; C Zietz; D Zhou; C Matteucci; G Peri; S Sozzani
Journal:  J Immunol       Date:  1994-11-15       Impact factor: 5.422

7.  Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome.

Authors:  F P Ognibene; R G Steis; A M Macher; L Liotta; E Gelmann; H I Pass; H C Lane; A S Fauci; J E Parrillo; H Masur
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

8.  The detection of acquired immunodeficiency syndrome-associated Kaposi sarcoma cells in pleural effusion by CD34 immunostain.

Authors:  G C Yang; J J Brooks; S Roberts; P K Gupta
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

9.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

10.  Propagation and properties of Kaposi's sarcoma-derived cell lines obtained from patients with AIDS: similarity of cultured cells to smooth muscle cells.

Authors:  A E Wittek; C D Mitchell; G R Armstrong; A Albini; G R Martin; R Seemann; I S Levenbook; D E Wierenga; J Ridge; R C Dunlap
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.